Mississauga, ON -- (SBWire) -- 01/25/2017 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "TG Therapeutics Receives New Orphan Drug Designation, Shares Rally On News"

Companies mentioned in this article include TG Therapeutics (NASDAQ:TGTX).

Article Excerpt:

The pharmaceuticals sector in the US is currently on pins and needles as it anxiously awaits an action plan from the new Trump government. While the sector anticipates to benefit from expected deregulation, it is also apprehensive about the likely caps on drug price increases. However, for companies working in niche areas that are developing treatments for more rare diseases are expected to keep up their performance. TG Therapeutics (NASDAQ:TGTX) is one such company which is currently working on two lead drug candidates.

The company received a big boost yesterday morning as its combination of TG-1101 and TGR-1202 received orphan drug designation from the FDA. The combination is being tested for treating patients with diffuse large B-cell lymphoma (DLBCL). The company said that DLBCL is a major area which has unmet medical requirements with any breakthrough in the field likely to be highly lucrative for the company.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/709/tg-therapeutics-receives-new-orphan-drug-designation-shares-rally-on-news.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999.

Investors can receive their free newsletter subscription by clicking here:
http://www.allpennystocks.com/aps_common/newsletter_free.asp

Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp